Anthem Biosciences reported a strong FY26 with revenue up 15.2% to ₹21,243 Mn. Profit after tax surged 31.1% to ₹5,918 Mn, with margins improving significantly. The company is investing ₹12,000 Mn in a new manufacturing unit to meet future demand.
Anthem Biosciences FY26 Results: Robust Growth and Expansion
Consolidated Revenue: ₹21,243 Mn
PAT: ₹5,918 Mn
Reader Takeaway: Strong profit growth and margin expansion driven by efficiencies, with significant investment in future capacity.
What just happened
Anthem Biosciences announced its financial results for the fiscal year 2025-26, showcasing a significant increase in both revenue and profitability. Consolidated revenue grew by 15.2% to ₹21,243 Mn, while profit after tax (PAT) surged by 31.1% to ₹5,918 Mn.
Why this matters
The robust growth indicates effective operational management and increasing demand for its services. The substantial increase in PAT, outpacing revenue growth, points to improved operating leverage and margin expansion. The company is also making strategic investments to scale its manufacturing capabilities.
The backstory
Anthem Biosciences recently debuted on Indian stock exchanges via an Offer for Sale (OFS) of ₹3,395 Mn, which facilitated the full exit of its private equity investor, True North. The company also launched the Anthem ESOP 2024 program to aid employee retention.
What changes now
The company is undertaking a significant expansion with the ground-breaking of a new greenfield manufacturing unit (Unit IV) in Harohalli, Bengaluru. This ₹12,000 Mn Phase I investment is intended to support future demand, particularly for high-growth areas such as Peptides and GLP-1 APIs.
Risks to watch
Investors should monitor the company's ability to navigate regulatory compliance, given its dependence on global audits from bodies like USFDA and TGA. Additionally, market concentration and exposure to global client cycles could impact revenue stability.
Peer comparison
While specific peer financial data for FY26 is not detailed in the filing, Anthem Biosciences' growth and margin expansion in FY26 show a strong performance trajectory. Its core business relies heavily on CRDMO Services, which contributed 83.4% of its revenue, with Specialty Ingredients making up the remaining 16.6%.
Context metrics (time-bound)
In FY 2025-26, consolidated revenue reached ₹21,243 Mn, a 15.2% increase from ₹18,446 Mn in FY 2025. EBITDA grew 30.8% to ₹9,896 Mn from ₹7,566 Mn. The EBITDA margin improved by 420 basis points to 43.4% from 39.2% in the prior year.
What to track next
Investors will be keen to track the progress of the new Unit IV commissioning and its contribution to future revenues. Maintaining high operating margins amidst increasing global competition and demand will also be a key factor to watch.